These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 29793653)

  • 1. Real-world Outcomes of Multiple Myeloma: Retrospective Analysis of the Czech Registry of Monoclonal Gammopathies.
    Hájek R; Jarkovsky J; Maisnar V; Pour L; Špička I; Minařík J; Gregora E; Kessler P; Sýkora M; Fraňková H; Campioni M; DeCosta L; Treur M; Gonzalez-McQuire S; Bouwmeester W
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):e219-e240. PubMed ID: 29793653
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib-based therapy for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation: Czech Registry Data.
    Sandecká V; Pour L; Špička I; Minařík J; Radocha J; Jelínek T; Heindorfer A; Pavlíček P; Sýkora M; Jungová A; Kessler P; Wróbel M; Starostka D; Ullrychová J; Stejskal L; Štork M; Straub J; Pika T; Brožová L; Ševčíková S; Maisnar V; Hájek R
    Eur J Haematol; 2021 Oct; 107(4):466-474. PubMed ID: 34272773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study.
    Mohty M; Terpos E; Mateos MV; Cavo M; Lejniece S; Beksac M; Bekadja MA; Legiec W; Dimopoulos M; Stankovic S; Durán MS; De Stefano V; Corso A; Kochkareva Y; Laane E; Berthou C; Salwender H; Masliak Z; Pečeliūnas V; Willenbacher W; Silva J; Louw V; Nemet D; Borbényi Z; Abadi U; Pedersen RS; Černelč P; Potamianou A; Couturier C; Feys C; Thoret-Bauchet F; Boccadoro M;
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):e401-e419. PubMed ID: 30030033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-World Use of 3rd Line Therapy for Multiple Myeloma in Austria: An Austrian Myeloma Registry (AMR) Analysis of the Therapeutic Landscape and Clinical Outcomes prior to the Use of Next Generation Myeloma Therapeutics.
    Willenbacher E; Weger R; Rochau U; Siebert U; Willenbacher W;
    PLoS One; 2016; 11(3):e0147381. PubMed ID: 26937956
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Asymptomatic and Treatment-requiring Multiple Myeloma - Data from the Czech Registry of Monoclonal Gammopathies.
    Brozova L; Jarkovský J; Pour L; Minárik J; Jungová A; Gregora E; Spicka I; Maisnar V; Hájek R
    Klin Onkol; 2017; 30(Supplementum2):51-59. PubMed ID: 28903571
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adjusted comparison of daratumumab monotherapy versus real-world historical control data from the Czech Republic in heavily pretreated and highly refractory multiple myeloma patients.
    Jelínek T; Maisnar V; Pour L; Špička I; Minařík J; Gregora E; Kessler P; Sýkora M; Fraňková H; Adamová D; Wróbel M; Mikula P; Jarkovský J; Diels J; Gatopoulou X; Veselá Š; Besson H; Brožová L; Ito T; Hájek R
    Curr Med Res Opin; 2018 May; 34(5):775-783. PubMed ID: 29172760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world treatment patterns and outcomes for patients with multiple myeloma in Denmark, Finland and Sweden: An analysis using linked Nordic registries.
    Abildgaard N; Anttila P; Waage A; Rubin KH; Ørstavik S; Bent-Ennakhil N; Gavini F; Ma Y; Freilich J; Hansson M
    Eur J Cancer; 2024 Apr; 201():113921. PubMed ID: 38377776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lenalidomide and dexamethasone in treatment of patients with relapsed and refractory multiple myeloma - analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.
    Maisnar V; Stefanikova Z; Spicka I; Pour L; Minarik J; Flochova E; Radocha J; Gregora E; Stecova N; Jelinek T; Jungova A; Kralikova E; Brozova L; Hajek R
    Neoplasma; 2019 May; 66(3):499-505. PubMed ID: 30784289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment pathways and disease journeys differ before and after introduction of novel agents in newly diagnosed multiple myeloma in Taiwan.
    Liu Y; Tang CH; Qiu H; Siggins S; Hou HA
    Sci Rep; 2021 Jan; 11(1):1112. PubMed ID: 33441901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model.
    Blommestein HM; Verelst SG; de Groot S; Huijgens PC; Sonneveld P; Uyl-de Groot CA
    Eur J Haematol; 2016 Feb; 96(2):198-208. PubMed ID: 25892333
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.
    Radocha J; Maisnar V; Pour L; Špička I; Minařík J; Szeligová L; Pavlíček P; Jungová A; Krejčí M; Pika T; Straub J; Brožová L; Stejskal L; Heindorfer A; Jindra P; Kessler P; Mikula P; Sýkora M; Wróbel M; Jarkovský J; Hájek R
    Cancer Med; 2018 Aug; 7(8):4132-4145. PubMed ID: 29931775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A prospective multi-center trial of non-interventional and observational study of lenalidomide in Chinese patients with multiple myeloma].
    Wang GM; Yang GZ; Huang ZX; Zhong YP; Jin FY; Liao AJ; Wang XM; Fu ZZ; Liu H; Li XL; Zhou JF; Zhang X; Hu Y; Meng FY; Huang XJ; Chen WM; Lu J
    Zhonghua Nei Ke Za Zhi; 2017 Jul; 56(7):500-506. PubMed ID: 28693058
    [No Abstract]   [Full Text] [Related]  

  • 14. Real-world treatment patterns, resource use and cost burden of multiple myeloma in Portugal.
    Antunes L; Rocha-Gonçalves F; Chacim S; Lefèvre C; Pereira M; Pereira S; Zagorska A; Bento MJ
    Eur J Cancer Care (Engl); 2019 Jul; 28(4):e13026. PubMed ID: 30828907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenalidomide in relapsed refractory myeloma patients: impact of previous response to bortezomib and thalidomide on treatment efficacy. Results of a medical need program in Belgium.
    Delforge M; Michiels A; Doyen C; Kentos A; Van Droogenbroeck J; Offner F; Bries G; Demuynck H; Vekemans MC; Meuleman N; Mineur PO; Ravoet C; Depryck B; Van de Velde A; Pierre P; Wu KL; Schots R
    Acta Clin Belg; 2011; 66(5):371-5. PubMed ID: 22145272
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the affordability of novel agents in patients with multiple myeloma: Real-world data of current clinical practice in Mexico.
    Tarín-Arzaga L; Arredondo-Campos D; Martínez-Pacheco V; Martínez-González O; Ramírez-López A; Gómez-De León A; Gutiérrez-Aguirre CH; Cantú-Rodríguez O; Jaime-Pérez JC; Gómez-Almaguer D
    Cancer; 2018 May; 124(9):1946-1953. PubMed ID: 29461639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world treatment patterns and associated progression-free survival in relapsed/refractory multiple myeloma among US community oncology practices.
    Jagannath S; Roy A; Kish J; Lunacsek O; Globe D; Eaddy M; Kuriakose ET; Willey J; Butler-Bird S; Siegel D
    Expert Rev Hematol; 2016 Jul; 9(7):707-17. PubMed ID: 27291638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Outcome and survival of myeloma patients diagnosed 2008-2015. Real-world data on 4904 patients from the Swedish Myeloma Registry.
    Blimark CH; Turesson I; Genell A; Ahlberg L; Björkstrand B; Carlson K; Forsberg K; Juliusson G; Linder O; Mellqvist UH; Nahi H; Kristinsson SY;
    Haematologica; 2018 Mar; 103(3):506-513. PubMed ID: 29217784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world analysis of patient characteristics, treatment outcomes, and healthcare resource utilization across Europe in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation who received lenalidomide- or bortezomib-based regimens.
    Zamagni E; Dhanasiri S; Ghale A; Moore A; Roussel M
    Leuk Lymphoma; 2021 Oct; 62(10):2492-2501. PubMed ID: 34121589
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real‑world multiple myeloma management practice patterns and outcomes in selected Central and Eastern European countries.
    Coriu D; Dytfeld D; Niepel D; Spicka I; Markuljak I; Mihaylov G; Ostojic-Kolonic S; Fink L; Toka KS; Björklöf K
    Pol Arch Intern Med; 2018 Sep; 128(9):500-511. PubMed ID: 30057386
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.